GSK submits sBLA seeking expanded indication for Flulaval Quadrivalent
GSK has submitted a supplemental Biologics License Application (sBLA) to the US Food and Drug Administration (FDA) for Flulaval Quadrivalent (Influenza Vaccine).
Click on this link for more information.
